Christophe Hilbert, senior manager of Access, Value, and Evidence Strategy, Europe at bluebird bio explores the problems of pricing and reimbursement for gene and cell therapies in Europe.
Tania Pereira Chilima, CTO at Univercells Technologies examines the challenges gene therapies face during production and how integrated and continuous processing can help.
Dr Clive Glover, director, Strategy, Pall Corporation discusses recent industry developments surrounding cell and gene therapies and why safety is a key priority for this treatment area.
Christopher Vakulskas, director of Enzyme Evolution at Integrated DNA Technologies explains how the company’s novel gene editing tools may one day provide single-treatment cures for diseases caused by single gene mutations, including sickle cell dise
Noel Maestre, advanced therapy medicinal product (ATMP) director at CRB guides readers through the steps needed to implement manufacturing strategies for advanced medicines.
CRISPR might have taken the world by storm but what’s next for gene editing technology? Ashley Jacobi, senior staff scientist at Integrated DNA Technologies (IDT) examines what's next.
Clive Glover, strategy director and cell and gene therapy lead at Pall Corporation, explains why we need to take a more holistic approach to gene therapy manufacturing processes.
